BioSpace News Archive

Morphic Holding, Inc. announced the closing of an underwritten public offering of 6,133,334 shares of its common stock at a price to the public of $45.00 per share, which includes 800,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares of common stock.

The American Association of Clinical Endocrinology announced the publication of the 2023 Comprehensive Type 2 Diabetes Management Algorithm, which provides concise guidance to assist healthcare professionals in clinical decision-making for the management of Type 2 diabetes.

The Combined Ordinary and Extraordinary General Meeting of Transgene’s shareholders was held at 9:00 a.m. at the Company’s headquarters.

Evolus, Inc. today announced that it will report its first quarter 2023 financial results and provide a business update on Tuesday, May 9, 2023, after the U.S. financial markets close.

Mereo BioPharma Group plc today announced that it has received approval from Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) to transfer the listing of its American Depositary Shares (“ADSs”) from the Nasdaq Global Market to the Nasdaq Capital Market.

TRxADE HEALTH INC. will release financial results for the first quarter 2023, after market close on May 15, 2023.

InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced today that Richard DiIorio, Chief Executive Officer, Barry Steele, Chief Financial Officer, and Carrie Lachance, President and Chief Operating Officer, will present at the Sidoti Micro-Cap Virtual Investor Conference at 9:15 a.m. ET on Thursday, May 11, 2023.

Algernon Pharmaceuticals Inc. announces that it has closed its previously announced rights offering which expired on April 27, 2023 (the “ Rights Offering ”).